{"schema_version":"secwatch.filing_event.v1","accession":"0002044820-26-000023","form_type":"8-K","ticker":null,"cik":"0002044820","company_name":"VistaOne, L.P.","filed_at":"2026-05-27T20:45:46+00:00","discovered_at":"2026-05-27T20:47:00.334570+00:00","generated_at":"2026-05-27T20:49:50.352244+00:00","sec_items":["3.02","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"VistaOne L.P. reports $23.6M unit sale, NAV per class, and $46.9M repurchase","bullets":["Sold 187,162 Class B, 500,054 Class I, and 79,673 Class S units for aggregate $23.6M.","Transactional NAV per unit as of April 30: Class A-I $30.88, Class E $32.29, Class R $25.17.","Repurchased 1,538,720 units at avg. $30.48/unit for total $46.9M.","Expense support agreement with Manager; reimbursement period expected no earlier than Oct 1, 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0002044820-26-000023","json":"https://secwatch.observer/filing/0002044820-26-000023.json","markdown":"https://secwatch.observer/filing/0002044820-26-000023.md","text":"https://secwatch.observer/filing/0002044820-26-000023.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2044820/000204482026000023/0002044820-26-000023-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2044820/000204482026000023/ck0002044820-20260520.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T20:49:50.352244+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"comparable_filings":[{"accession":"0001193125-26-251789","ticker":"GIPR","company_name":"GENERATION INCOME PROPERTIES, INC.","filed_at":"2026-06-01T21:27:59+00:00","headline":"Generation Income Properties prices $5.0M public offering of 23.8M shares and warrants at $0.21/unit","event_type":"other_material","sec_items":["1.01","8.01","9.01"],"materiality_score":0.6,"calibrated_materiality_score":0.6,"match_reasons":["same SEC item: 8.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-251789","json":"https://secwatch.observer/filing/0001193125-26-251789.json","markdown":"https://secwatch.observer/filing/0001193125-26-251789.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1651721/000119312526251789/0001193125-26-251789-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1651721/000119312526251789/gipr-20260528.htm"},"side_by_side_evidence":null},{"accession":"0001104659-26-069016","ticker":"MUX","company_name":"McEwen Inc.","filed_at":"2026-06-01T21:14:20+00:00","headline":"McEwen receives $49.4M dividend from Minera Santa Cruz; total 2026 dividends now $58.2M","event_type":"other_material","sec_items":["8.01","9.01"],"materiality_score":0.6,"calibrated_materiality_score":0.6,"match_reasons":["same SEC item: 8.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-069016","json":"https://secwatch.observer/filing/0001104659-26-069016.json","markdown":"https://secwatch.observer/filing/0001104659-26-069016.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/314203/000110465926069016/0001104659-26-069016-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/314203/000110465926069016/tm2616562d1_8ka.htm"},"side_by_side_evidence":null},{"accession":"0001796022-26-000002","ticker":"STEP","company_name":"StepStone Group Inc.","filed_at":"2026-06-01T20:55:45+00:00","headline":"StepStone completes third exchange, now owns 65% of three asset class entities","event_type":"other_material","sec_items":["3.02","8.01"],"materiality_score":0.55,"calibrated_materiality_score":0.55,"match_reasons":["same SEC item: 3.02, 8.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001796022-26-000002","json":"https://secwatch.observer/filing/0001796022-26-000002.json","markdown":"https://secwatch.observer/filing/0001796022-26-000002.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1796022/000179602226000002/0001796022-26-000002-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1796022/000179602226000002/step-20260529.htm"},"side_by_side_evidence":null},{"accession":"0001449794-26-000012","ticker":"EMYB","company_name":"Embassy Bancorp, Inc.","filed_at":"2026-06-01T20:37:17+00:00","headline":"Embassy Bancorp expands stock repurchase program by additional $5M","event_type":"other_material","sec_items":["8.01","9.01"],"materiality_score":0.5,"calibrated_materiality_score":0.5,"match_reasons":["same SEC item: 8.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001449794-26-000012","json":"https://secwatch.observer/filing/0001449794-26-000012.json","markdown":"https://secwatch.observer/filing/0001449794-26-000012.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1449794/000144979426000012/0001449794-26-000012-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1449794/000144979426000012/emyb-20260601x8k.htm"},"side_by_side_evidence":null},{"accession":"0001213900-26-063531","ticker":"CTXR","company_name":"Citius Pharmaceuticals, Inc.","filed_at":"2026-06-01T20:30:19+00:00","headline":"Citius Oncology reports Phase 1 combo data: 24% ORR, 33% in endometrial cancer; Phase 2 planned","event_type":"other_material","sec_items":["8.01","9.01"],"materiality_score":0.5,"calibrated_materiality_score":0.5,"match_reasons":["same SEC item: 8.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-063531","json":"https://secwatch.observer/filing/0001213900-26-063531.json","markdown":"https://secwatch.observer/filing/0001213900-26-063531.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1506251/000121390026063531/0001213900-26-063531-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1506251/000121390026063531/ea0292904-8k_citius.htm"},"side_by_side_evidence":null},{"accession":"0001213900-26-063530","ticker":"CTOR","company_name":"CITIUS ONCOLOGY, INC.","filed_at":"2026-06-01T20:30:18+00:00","headline":"Citius Oncology reports Phase 1 combo data for LYMPHIR in gynecologic cancers; 24% ORR, 33% in endometrial cancer","event_type":"other_material","sec_items":["8.01","9.01"],"materiality_score":0.6,"calibrated_materiality_score":0.6,"match_reasons":["same SEC item: 8.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-063530","json":"https://secwatch.observer/filing/0001213900-26-063530.json","markdown":"https://secwatch.observer/filing/0001213900-26-063530.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1851484/000121390026063530/0001213900-26-063530-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1851484/000121390026063530/ea0292903-8k_citius.htm"},"side_by_side_evidence":null},{"accession":"0001683168-26-004423","ticker":"CITR","company_name":"CitroTech Inc.","filed_at":"2026-06-01T20:15:28+00:00","headline":"CitroTech exchanges all Series A Preferred for Series C Convertible; BoltRock gets board rights","event_type":"other_material","sec_items":["1.01","3.02","9.01"],"materiality_score":0.6,"calibrated_materiality_score":0.6,"match_reasons":["same SEC item: 3.02, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-26-004423","json":"https://secwatch.observer/filing/0001683168-26-004423.json","markdown":"https://secwatch.observer/filing/0001683168-26-004423.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/894556/000168316826004423/0001683168-26-004423-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/894556/000168316826004423/citro_8k.htm"},"side_by_side_evidence":null},{"accession":"0001636282-26-000075","ticker":"SYRE","company_name":"Spyre Therapeutics, Inc.","filed_at":"2026-06-01T20:01:39+00:00","headline":"Spyre Therapeutics expands SPY003 license field beyond IBD with dosing restrictions until 2028-2030","event_type":"other_material","sec_items":["8.01","9.01"],"materiality_score":0.55,"calibrated_materiality_score":0.55,"match_reasons":["same SEC item: 8.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001636282-26-000075","json":"https://secwatch.observer/filing/0001636282-26-000075.json","markdown":"https://secwatch.observer/filing/0001636282-26-000075.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1636282/000163628226000075/0001636282-26-000075-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1636282/000163628226000075/syre-20260529.htm"},"side_by_side_evidence":null}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}